- Home
- TALO vs CNTA Comparison
TALO vs CNTA Comparison
Compare TALO & CNTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TALO | CNTA |
|---|---|---|
| Founded | 2011 | 2020 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 2.3B |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | TALO | CNTA |
|---|---|---|
| Price | $11.49 | $26.51 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 11 |
| Target Price | $14.30 | ★ $37.70 |
| AVG Volume (30 Days) | ★ 2.1M | 1.8M |
| Earning Date | 11-05-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,872,554,000.00 | $15,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 0.06 | ★ 118.88 |
| 52 Week Low | $6.23 | $9.60 |
| 52 Week High | $12.20 | $30.58 |
Technical Indicators
Market Signals| Indicator | TALO | CNTA |
|---|---|---|
| Relative Strength Index (RSI) | 57.53 | 45.51 |
| Support Level | $11.55 | $28.43 |
| Resistance Level | $11.96 | $30.02 |
| Average True Range (ATR) | 0.39 | 1.34 |
| MACD | -0.04 | -0.40 |
| Stochastic Oscillator | 47.45 | 18.64 |
Price Performance
Historical ComparisonAbout TALO Talos Energy Inc.
Talos Energy Inc is an independent oil and gas company predominantly involved in offshore exploration and production. The company has operations in the United States, the Gulf of Mexico, and offshore Mexico. The company's operating segments are; exploration and production of oil, natural gas and NGLs, and the CCS segment. The revenue is generated from the sale of oil, natural gas, and NGL quantities sold to purchasers.
About CNTA Centessa Pharmaceuticals plc
Centessa Pharmaceuticals PLC is a clinical-stage pharmaceutical company. The company's pipeline assets include: SerpinPC for Hemophilia A, B; LB101 for Solid Tumors; ORX750 for Narcolepsy Type 1 (NT1) and other sleep disorders; MGX292 Pulmonary Arterial Hypertension (PAH); and Undisclosed for Solid Tumors.